8-K: BIOLASE, Inc. Reports 30.8 Million Shares Outstanding

BIOLASE, Inc. disclosed that it had 30,796,754 shares of common stock outstanding as of February 26, 2024.

Summary

• BIOLASE, Inc. filed a Form 8-K report on February 27, 2024.
• The report indicates that as of February 26, 2024, the company had 30,796,754 shares of common stock outstanding.
• The common stock has a par value of $0.001 per share.

Sentiment

Score: 5

Explanation: The document is a neutral disclosure of share count, which is neither positive nor negative in itself.

Management Comments

• John R. Beaver, Chief Executive Officer, signed the report on behalf of BIOLASE, Inc.

Industry Context

This is a standard disclosure of share count, which is a routine filing for public companies and is important for investors to understand the company's capital structure.

Comparison to Industry Standards

• The disclosure of shares outstanding is a standard practice for all publicly traded companies, including those in the medical device industry such as Align Technology (ALGN) and Dentsply Sirona (XRAY).
• These companies also regularly report their share counts in their SEC filings.

Stakeholder Impact

• This information is relevant to shareholders as it provides an update on the total number of shares outstanding, which is important for calculating ownership percentages and per-share metrics.

Key Dates

Keywords

common stock, shares outstanding, BIOLASE, equity, capitalization